Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

NAMS

NewAmsterdam Pharma Company NV

Feb 13 • 04:00PM ET

34.63

-0.23 -0.66 %

Healthcare • Biotechnology • Netherlands • NASD

Peers: JNJ PFE MRK BMY LLY GILD AMGN REGN VRTX BIIB

| Held by: IBB CGMM FYC VHT SBIO FYX FFSM ONEQ ESML FHLC

Index	-	P/E	-	EPS (ttm)	-2.04	Insider Own	29.12%	Shs Outstand	113.17M	Perf Week	0.96%
Market Cap	3.93B	Forward P/E	-	EPS next Y	-1.65	Insider Trans	-2.01%	Shs Float	80.37M	Perf Month	8.49%
Enterprise Value	3.22B	PEG	-	EPS next Q	-0.40	Inst Own	68.68%	Short Float	8.84%	Perf Quarter	-9.61%
Income	-221.07M	P/S	111.43	EPS this Y	42.04%	Inst Trans	4.83%	Short Ratio	8.37	Perf Half Y	37.58%
Sales	35.24M	P/B	5.38	EPS next Y	-11.32%	ROA	-36.08%	Short Interest	7.10M	Perf YTD	-1.28%
Book/sh	6.43	P/C	5.58	EPS next 5Y	22.30%	ROE	-39.94%	52W High	42.00 -17.55%	Perf Year	78.51%
Cash/sh	6.21	P/FCF	-	EPS past 3/5Y	-22.27% -	ROIC	-30.36%	52W Low	14.06 146.30%	Perf 3Y	169.08%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	99.40%	Volatility	4.66% 4.69%	Perf 5Y	225.47%
Dividend TTM	-	EV/Sales	91.45	EPS Y/Y TTM	-896.05%	Oper. Margin	-575.81%	ATR (14)	1.60	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	12.57	Sales Y/Y TTM	-	Profit Margin	-627.28%	RSI (14)	54.84	Recom	1.13
Dividend Gr. 3/5Y	- -	Current Ratio	12.57	EPS Q/Q	-244.39%	SMA20	4.45%	Beta	0.05	Target Price	49.00
Payout	-	Debt/Eq	0.00	Sales Q/Q	-98.80%	SMA50	1.47%	Rel Volume	1.04	Prev Close	34.86
Employees	68	LT Debt/Eq	0.00	Earnings	Nov 05 BMO	SMA200	22.37%	Avg Volume	848.71K	Price	34.63
IPO	Feb 08, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	-55.47% -93.44%	Trades		Volume	883,668	Change	-0.66%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-20-25	Resumed	H.C. Wainwright	Buy	$52
Aug-25-25	Initiated	Wells Fargo	Overweight	$45
Jul-17-25	Initiated	Goldman	Neutral	$27
Jun-17-25	Initiated	Citigroup	Buy	$42
Jun-10-25	Initiated	Stifel	Buy	$44
Jun-04-25	Initiated	Cantor Fitzgerald	Overweight	$42
Dec-30-24	Initiated	H.C. Wainwright	Buy	$48
May-15-24	Initiated	TD Cowen	Buy
Mar-14-24	Initiated	Scotiabank	Sector Outperform	$35
Jan-18-24	Initiated	Guggenheim	Buy	$30
Jan-16-24	Initiated	Piper Sandler	Overweight	$37
Oct-30-23	Initiated	RBC Capital Mkts	Outperform	$25

Show Previous Ratings

Feb-06-26 04:01PM	NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.99%
Feb-04-26 08:00AM	NewAmsterdam Pharma to Present at the Guggenheim Emerging Outlook: Biotech Summit (GlobeNewswire)
Jan-09-26 08:00AM	NewAmsterdam Pharma Highlights 2025 Achievements and Outlines 2026 Strategic Priorities (GlobeNewswire)
Jan-06-26 07:54AM	NewAmsterdam Pharma Company N.V. (NAMS) Shares Spiked by 57% in Q3 (Insider Monkey)
Jan-05-26 04:01PM	NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
06:50PM	Loading…
Dec-12-25 06:50PM	National Presto, Garrett Motion, and More Stocks See Action From Activist Investors (Barrons.com) -5.10%
Dec-05-25 04:01PM	NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-25-25 08:00AM	NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in December (GlobeNewswire)
Nov-07-25 04:01PM	NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.01%
Nov-05-25 09:15AM	NewAmsterdam Pharma Company N.V. (NAMS) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
08:00AM	NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results (GlobeNewswire)
Nov-04-25 08:20AM	Madrigal (MDGL) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
Oct-30-25 08:00AM	NewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Investor Conferences in November (GlobeNewswire) +8.05%
Oct-29-25 10:00AM	NewAmsterdam Pharma Company N.V. (NAMS) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Oct-24-25 07:31AM	Enteras oral osteoporosis drug meets endpoints in Phase II trial (Clinical Trials Arena)
06:20PM	Loading…
Oct-10-25 06:20PM	8Dell, 89bio, MBX Biosciences and More Stocks See Action From Activist Investors (Barrons.com) +12.26%
Oct-07-25 06:04AM	NewAmsterdam Pharma Company N.V. (NAMS) Soars 5.9%: Is Further Upside Left in the Stock? (Zacks)
Sep-24-25 08:00AM	NewAmsterdam Pharma to Present at the Stifel 2025 Virtual Cardiometabolic Forum (GlobeNewswire)
Aug-29-25 04:30PM	Core Scientific, NewAmsterdam Pharma, and More Stocks See Action From Activist Investors (Barrons.com)
Aug-25-25 08:00AM	NewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Investor Conferences in September (GlobeNewswire)
Aug-18-25 08:00AM	NewAmsterdam Announces Acceptance of Marketing Authorization Applications for Review by European Medicine Agency for Obicetrapib (GlobeNewswire)
Aug-06-25 08:30AM	NewAmsterdam Pharma Company N.V. (NAMS) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +8.70%
07:00AM	NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results (GlobeNewswire)
Jul-30-25 08:25AM	NewAmsterdam Pharma Presents Positive Data from BROADWAY Trial Demonstrating Statistically Significant Reductions in Key Alzheimer's Disease Biomarkers at AAIC 2025 (GlobeNewswire)
Jul-22-25 08:00AM	NewAmsterdam Pharma to Present Alzheimer's Biomarker Data from BROADWAY Trial at AAIC 2025 (GlobeNewswire)
Jul-16-25 09:38AM	Jefferies Remains Bullish on NewAmsterdam Pharma (NAMS) (Insider Monkey)
Jun-17-25 12:57PM	Citi initiates coverage on biotech amid improving sentiment in sector (Investing.com) -6.38%
Jun-11-25 08:06PM	NewAmsterdam Pharma Company N.V. (NAMS) Initiated with a Buy at Stifel (Insider Monkey) -6.14%
Jun-09-25 07:00AM	NewAmsterdam Pharma Announces Positive Topline Alzheimer's Disease Data from BROADWAY Clinical Trial (GlobeNewswire)
Jun-05-25 08:00AM	NewAmsterdam Pharma to Host R&D Day on June 11, 2025 (GlobeNewswire)
08:00AM	Loading…
May-27-25 08:00AM	NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June (GlobeNewswire)
May-14-25 08:00AM	NewAmsterdam Pharma to Present at the 2025 RBCCM Global Healthcare Conference (GlobeNewswire)
May-12-25 09:55AM	Wall Street Analysts Predict a 132.5% Upside in NewAmsterdam Pharma Company N.V. (NAMS): Here's What You Should Know (Zacks)
May-08-25 09:30AM	NewAmsterdam Pharma Company N.V. (NAMS) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
08:15AM	Akebia Therapeutics (AKBA) Q1 Earnings and Revenues Top Estimates (Zacks)
08:00AM	NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results (GlobeNewswire)
May-07-25 07:15AM	NewAmsterdam Pharma Announces Late-Breaking Data from BROADWAY and TANDEM Pivotal Studies Published in Leading Medical Journals and Presented at the European Atherosclerosis Society (EAS) Congress 2025 (GlobeNewswire)
May-02-25 04:01PM	NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-30-25 08:00AM	NewAmsterdam Pharma to Present New Clinical and Preclinical Data at 93rd EAS Congress (GlobeNewswire)
Apr-29-25 11:40AM	NewAmsterdam Pharma Company N.V. (NAMS): Among Billionaire Andreas Halvorsen's Stock Picks With Huge Upside Potential (Insider Monkey)
Apr-23-25 01:01PM	Is NewAmsterdam Pharma Company N.V. (NAMS) Among the Best Guru Stocks to Buy According to Wall Street Analysts? (Insider Monkey)
Apr-17-25 04:01PM	NewAmsterdam Pharma Appoints Adele Gulfo to its Board of Directors (GlobeNewswire)
Apr-11-25 04:23PM	NewAmsterdam Pharma (NAMS): Among Billionaire Stanley Druckenmiller's Top Stock Picks with Huge Upside Potential (Insider Monkey) +8.60%
Apr-04-25 04:01PM	NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -12.17%
Mar-31-25 04:18PM	Does AstraZeneca Have 'One Pill To Rule Them All' In Cholesterol? (Investor's Business Daily) -5.93% -10.21%
08:00AM	NewAmsterdam Pharma to Present at the 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-30-25 07:10AM	abrdn World Healthcare Fund Q4 2024 Commentary (Seeking Alpha)
Feb-26-25 08:00AM	NewAmsterdam Pharma Reports Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire) +10.23%
Feb-25-25 08:00AM	NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March (GlobeNewswire)
Feb-07-25 04:01PM	NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-29-25 08:00AM	NewAmsterdam Pharma to Present at Guggenheim's SMID Cap Biotech Conference (GlobeNewswire)
Jan-10-25 08:00AM	NewAmsterdam Pharma Highlights 2024 Achievements and Outlines 2025 Strategic Priorities (GlobeNewswire)
Jan-09-25 03:38PM	NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-13-24 05:16PM	NewAmsterdam Pharma Announces Closing of Upsized $479.0 Million Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Dec-11-24 09:37PM	NewAmsterdam Pharma Announces Pricing of Upsized $416.5 Million Public Offering of Ordinary Shares and Pre-Funded Warrants (GlobeNewswire)
03:06PM	NewAmsterdam Pharma Stock Hits 90-Plus RS Rating (Investor's Business Daily)
Dec-10-24 05:10PM	NewAmsterdam Pharma Soars 41% On A Surprise Benefit From Cholesterol Drug (Investor's Business Daily) +41.41%
04:34PM	NewAmsterdam Pharma Announces Commencement of $300 Million Public Offering of Ordinary Shares and Pre-Funded Warrants (GlobeNewswire)
07:00AM	NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (GlobeNewswire)
Dec-06-24 04:01PM	NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-21-24 07:37AM	NewAmsterdam Pharma Reports Promising Phase 3 Trial Results (TipRanks)
Nov-20-24 04:13PM	NewAmsterdam Dives And Sacrifices A Cup Base Despite A Winning Cholesterol Study (Investor's Business Daily) -15.50%
07:00AM	NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 TANDEM Clinical Trial Evaluating the Fixed-Dose Combination of Obicetrapib 10 mg and Ezetimibe 10 mg in Patients with ASCVD or ASCVD Risk Factors and/or HeFH (GlobeNewswire)
Nov-18-24 03:20PM	NewAmsterdam Pharma Presents Additional Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia at AHA Scientific Sessions 2024 (GlobeNewswire)
Nov-06-24 08:00AM	NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results (GlobeNewswire) +13.73%
Nov-01-24 05:26PM	NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-28-24 04:30PM	NewAmsterdam Pharma to Participate in Upcoming Medical and Investor Conferences in November (GlobeNewswire)
Oct-04-24 04:30PM	NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-06-24 04:32PM	NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-30-24 08:00AM	NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in September (GlobeNewswire)
Aug-07-24 08:00AM	NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results (GlobeNewswire)
Aug-02-24 04:01PM	NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.35%
Jul-29-24 08:54AM	NewAmsterdam Touts Cholesterol Drug Success, But Results Trail Analysts' Expectations (Investor's Business Daily) -8.54%
08:00AM	NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia (GlobeNewswire)
Jul-26-24 04:01PM	NewAmsterdam Pharma to Announce Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia on Monday, July 29, 2024 (GlobeNewswire)
Jul-18-24 08:00AM	NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors (GlobeNewswire)
Jul-08-24 08:00AM	NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib plus Ezetimibe in Patients with HeFH and/or ASCVD or ASCVD Risk Factors (GlobeNewswire)
Jul-03-24 04:01PM	NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-11-24 08:00AM	NewAmsterdam Pharma Announces Issuance of Composition of Matter Patent for Obicetrapib by the United States Patent and Trademark Office (GlobeNewswire)
Jun-07-24 04:01PM	NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-29-24 08:00AM	NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in June (GlobeNewswire)
May-21-24 08:00AM	NewAmsterdam Pharma to Present New Clinical and Preclinical Data Highlighting Obicetrapib's Impact on Key Risk Factors for Cardiovascular Disease at Upcoming Medical Meetings (GlobeNewswire)
May-09-24 08:00AM	NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results (GlobeNewswire)
May-03-24 04:01PM	NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-02-24 08:00AM	NewAmsterdam Pharma to Host R&D Day with Key Opinion Leaders on May 16, 2024 (GlobeNewswire)
Apr-09-24 08:00AM	NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease (GlobeNewswire)
Apr-01-24 08:00AM	NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer (GlobeNewswire) -9.64%
Mar-25-24 08:00AM	NewAmsterdam Pharma to Present New Analysis from the Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe at 2024 American College of Cardiology Congress (GlobeNewswire)
Mar-13-24 01:32PM	NewAmsterdam (NAMS) Doses Patient in HeFH Study, Shares Up (Zacks)
Mar-12-24 08:00AM	NewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with HeFH and/or ASCVD (GlobeNewswire) +11.89%
Feb-28-24 08:33AM	NewAmsterdam Pharma Co NV (NAMS) Faces Net Loss in 2023 Despite Clinical Progress (GuruFocus.com)
08:00AM	NewAmsterdam Pharma Reports Full Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-26-24 08:00AM	NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in March (GlobeNewswire)
Feb-13-24 10:40PM	NewAmsterdam Pharma Announces Pricing of $175.3 Million Public Offering of Ordinary Shares and Pre-Funded Warrants (GlobeNewswire)
04:01PM	NewAmsterdam Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants (GlobeNewswire)
Feb-01-24 04:01PM	NewAmsterdam Pharma to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference (GlobeNewswire) -6.01%
Jan-08-24 08:00AM	NewAmsterdam Pharma Appoints William H. Lewis, J.D., M.B.A. as Chair of its Board of Directors (GlobeNewswire)
Jan-04-24 08:00AM	NewAmsterdam Pharma Announces 2024 Strategic Priorities (GlobeNewswire)
Nov-13-23 09:55AM	Forbion co-leads 129 million Series A financing of VectorY, one of the largest private biotech financings in Europe in 2023 (GlobeNewswire) -6.91%
08:00AM	NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter 2023 Financial Highlights (GlobeNewswire)

NewAmsterdam Pharma Co. NV is a clinical-stage biopharmaceutical company, which engages in the development of oral, non-statin medicine for patients at high risk of cardiovascular disease with residual elevation of low-density lipoprotein cholesterol. Its lead product candidate, Obicetrapib, is a next-generation, oral, low-dose cholesteryl ester transfer protein inhibitor, which will be used to prevent major adverse cardiovascular events. The company was founded on June 10, 2022 and is headquartered in Naarden, the Netherlands.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kooij Louise Frederika	Chief Accounting Officer	Jan 27 '26	Option Exercise	10.90	39,816	433,994	64,169	Jan 29 04:40 PM
Kooij Louise Frederika	Chief Accounting Officer	Jan 28 '26	Option Exercise	10.90	32,612	355,471	56,965	Jan 29 04:40 PM
Kooij Louise Frederika	Chief Accounting Officer	Jan 27 '26	Sale	32.62	39,816	1,298,798	24,353	Jan 29 04:40 PM
Kooij Louise Frederika	Chief Accounting Officer	Jan 28 '26	Sale	31.80	32,612	1,037,062	24,353	Jan 29 04:40 PM
Kooij Louise Frederika	Chief Accounting Officer	Jan 23 '26	Option Exercise	10.90	38,172	416,075	62,525	Jan 27 05:38 PM
Kooij Louise Frederika	Chief Accounting Officer	Jan 26 '26	Option Exercise	10.90	34,400	374,960	58,753	Jan 27 05:38 PM
Kooij Louise Frederika	Chief Accounting Officer	Jan 23 '26	Sale	33.75	38,172	1,288,345	24,353	Jan 27 05:38 PM
Kooij Louise Frederika	Chief Accounting Officer	Jan 26 '26	Sale	32.78	34,400	1,127,498	24,353	Jan 27 05:38 PM
Somaiya Mayur Ian	Chief Financial Officer	Jan 20 '26	Option Exercise	9.26	60,216	557,600	118,598	Jan 22 05:24 PM
Somaiya Mayur Ian	Chief Financial Officer	Jan 21 '26	Option Exercise	9.26	39,784	368,400	98,166	Jan 22 05:24 PM
Somaiya Mayur Ian	Chief Financial Officer	Jan 20 '26	Sale	31.96	60,216	1,924,401	58,382	Jan 22 05:24 PM
Somaiya Mayur Ian	Chief Financial Officer	Jan 21 '26	Sale	33.59	39,784	1,336,217	58,382	Jan 22 05:24 PM
Mayur Somaiya	Affiliate	Jan 20 '26	Proposed Sale	31.65	200,000	6,330,000		Jan 20 04:17 PM
Kastelein Johannes Jacob Piete	Chief Scientific Officer	Jan 05 '26	Sale	33.25	6,000	199,500	73,481	Jan 07 06:31 PM
Kooij Louise Frederika	Chief Accounting Officer	Jan 05 '26	Sale	33.25	2,647	88,013	12,353	Jan 07 06:27 PM
Somaiya Mayur Ian	Chief Financial Officer	Jan 05 '26	Sale	33.25	5,118	170,174	32,882	Jan 07 06:27 PM
Michael Davidson	affiliate	Jan 07 '26	Proposed Sale	35.48	11,582	410,889		Jan 07 01:19 PM
Douglas F Kling	Affiliate	Jan 06 '26	Proposed Sale	33.48	300,000	10,044,000		Jan 06 04:29 PM
Louise Kooij	affiliate	Jan 05 '26	Proposed Sale	33.25	2,647	88,012		Jan 05 03:18 PM
Johannes Kastelein	Affiliate	Jan 05 '26	Proposed Sale	33.25	6,000	199,499		Jan 05 03:04 PM
Mayur Ian Somaiya	affiliate	Jan 05 '26	Proposed Sale	33.25	5,118	170,173		Jan 05 03:03 PM
Kooij Louise Frederika	Chief Accounting Officer	Dec 23 '25	Option Exercise	10.00	75,117	751,170	90,117	Dec 29 05:14 PM
Kooij Louise Frederika	Chief Accounting Officer	Dec 26 '25	Option Exercise	10.10	43,872	443,220	58,872	Dec 29 05:14 PM
Kooij Louise Frederika	Chief Accounting Officer	Dec 24 '25	Option Exercise	10.00	26,011	260,110	41,011	Dec 29 05:14 PM
Kooij Louise Frederika	Chief Accounting Officer	Dec 23 '25	Sale	36.21	75,117	2,719,987	15,000	Dec 29 05:14 PM
Kooij Louise Frederika	Chief Accounting Officer	Dec 26 '25	Sale	35.30	43,872	1,548,682	15,000	Dec 29 05:14 PM
Kooij Louise Frederika	Chief Accounting Officer	Dec 24 '25	Sale	35.68	26,011	928,072	15,000	Dec 29 05:14 PM
Louise Kooij	Officer	Dec 23 '25	Proposed Sale	36.49	290,000	10,582,100		Dec 23 05:31 PM
Bain Capital Life Sciences Fun	Former Affiliate	Dec 02 '25	Proposed Sale	38.33	267,429	10,250,554		Dec 02 09:25 PM
BCLS II Investco, LP	Former Affiliate	Dec 02 '25	Proposed Sale	38.33	4,500,000	172,485,000		Dec 02 09:23 PM
BCIP Life Sciences Associates,	Former Affiliate	Dec 02 '25	Proposed Sale	38.33	32,571	1,248,446		Dec 02 09:22 PM
Topper James N	Director	Sep 15 '25	Buy	23.70	660	15,639	3,028,524	Sep 17 05:22 PM
Kooij Louise Frederika	Chief Accounting Officer	Sep 09 '25	Option Exercise	10.00	150,000	1,500,000	165,000	Sep 10 05:39 PM
Kooij Louise Frederika	Chief Accounting Officer	Sep 09 '25	Sale	25.83	150,000	3,874,017	15,000	Sep 10 05:39 PM
Topper James N	Director	Sep 08 '25	Buy	24.99	1,260	31,487	3,027,864	Sep 10 05:19 PM
Louise Kooij	Affiliate	Sep 09 '25	Proposed Sale	25.20	150,000	3,780,000		Sep 09 11:57 AM
Kooij Louise Frederika	Chief Accounting Officer	Sep 03 '25	Sale	25.09	18,073	453,452	15,000	Sep 05 05:06 PM
Kooij Louise Frederika	Officer	Sep 03 '25	Proposed Sale	24.05	18,073	434,656		Sep 03 08:21 AM
Kooij Louise Frederika	Chief Accounting Officer	Aug 25 '25	Sale	24.86	8,269	205,567	15,000	Aug 27 05:08 PM
Kooij Louise Frederika	Officer	Aug 25 '25	Proposed Sale	25.19	8,269	208,296		Aug 27 04:57 PM
Kastelein Johannes Jacob Piete	Chief Scientific Officer	Aug 22 '25	Sale	25.14	50,000	1,257,140	69,302	Aug 25 05:04 PM
Kastelein Johannes Jacob Piete	Chief Scientific Officer	Aug 21 '25	Sale	24.29	50,000	1,214,500	119,302	Aug 25 05:04 PM
Kastelein Johannes Jacob Piete	Officer	Aug 21 '25	Proposed Sale	25.00	100,000	2,500,000		Aug 25 05:03 PM
Topper James N	Director	Aug 11 '25	Buy	23.98	471	11,294	3,026,604	Aug 13 04:49 PM
Kling Douglas F	Chief Operating Officer	Jul 16 '25	Option Exercise	10.90	51,043	556,369	95,043	Jul 17 05:19 PM
Kling Douglas F	Chief Operating Officer	Jul 15 '25	Option Exercise	10.90	47,569	518,502	91,569	Jul 17 05:19 PM
Kling Douglas F	Chief Operating Officer	Jul 16 '25	Sale	21.10	51,043	1,077,007	44,000	Jul 17 05:19 PM
Kling Douglas F	Chief Operating Officer	Jul 15 '25	Sale	21.44	47,569	1,019,648	44,000	Jul 17 05:19 PM
NAP PoolCo B.V.	Affiliate	Jul 14 '25	Proposed Sale	21.56	1,433,193	30,899,641		Jul 14 04:12 PM
Topper James N	Director	Jun 24 '25	Buy	18.43	2,520	46,454	3,024,873	Jun 26 07:41 PM
Topper James N	Director	Jun 25 '25	Buy	18.26	1,260	23,012	3,026,133	Jun 26 07:41 PM
Kling Douglas F	Chief Operating Officer	Jun 16 '25	Option Exercise	10.20	100,000	1,019,709	144,000	Jun 18 04:50 PM
Kling Douglas F	Chief Operating Officer	Jun 16 '25	Sale	19.29	100,000	1,929,141	44,000	Jun 18 04:50 PM
Topper James N	Director	Jun 16 '25	Buy	19.50	8,584	167,381	3,022,153	Jun 18 04:42 PM
NAP PoolCo B.V.	Affiliate	Jun 16 '25	Proposed Sale	19.50	303,197	5,912,342		Jun 18 12:31 PM
LANGE LOUIS G	Director	Jun 01 '25	Option Exercise	0.00	68	0	28,186	Jun 03 04:59 PM
Kling Douglas F	Chief Operating Officer	May 15 '25	Option Exercise	10.00	100,000	1,000,000	144,000	May 19 04:44 PM
Douglas F Kling	Affiliate	May 15 '25	Proposed Sale	18.75	298,612	5,598,975		May 15 04:40 PM
LANGE LOUIS G	Director	May 01 '25	Option Exercise	0.00	69	0	28,118	May 02 04:55 PM
LANGE LOUIS G	Director	Apr 14 '25	Option Exercise	0.00	69	0	28,049	Apr 21 05:41 PM
Kling Douglas F	Chief Operating Officer	Apr 15 '25	Option Exercise	10.00	100,000	1,000,000	144,000	Apr 17 05:41 PM
NAP PoolCo B.V.	Affiliate	Apr 11 '25	Proposed Sale	15.12	1,433,193	21,669,878		Apr 11 05:04 PM
Topper James N	Director	Mar 26 '25	Buy	22.49	1,135	25,521	3,013,569	Mar 28 05:36 PM
Kooij Louise Frederika	Chief Accounting Officer	Mar 26 '25	Option Exercise	0.00	8,269	0	23,269	Mar 28 05:29 PM
LANGE LOUIS G	Director	Mar 26 '25	Option Exercise	0.00	3,102	0	10,062	Mar 28 05:24 PM
Kastelein Johannes Jacob Piete	Chief Scientific Officer	Mar 26 '25	Option Exercise	0.00	45,481	0	79,481	Mar 28 05:20 PM
Kling Douglas F	Chief Operating Officer	Mar 26 '25	Option Exercise	0.00	16,539	0	60,539	Mar 28 05:18 PM
Davidson Michael H.	Chief Executive Officer	Mar 26 '25	Option Exercise	0.00	38,394	0	402,699	Mar 28 05:15 PM
Michael H. Davidson	Affiliate	Mar 26 '25	Proposed Sale	23.41	12,258	286,960		Mar 26 06:19 PM
Douglas F Kling	Affiliate	Mar 26 '25	Proposed Sale	23.41	16,539	387,178		Mar 26 06:00 PM
Kling Douglas F	Chief Operating Officer	Mar 17 '25	Option Exercise	10.00	11,888	118,880	144,000	Mar 19 05:29 PM
Topper James N	Director	Mar 04 '25	Buy	21.02	4,005	84,203	3,012,434	Mar 06 05:32 PM
Kooij Louise Frederika	Chief Accounting Officer	Mar 04 '25	Sale	20.37	150,000	3,055,500	15,000	Mar 05 06:10 PM
Kooij Louise Frederika	Officer	Mar 04 '25	Proposed Sale	20.27	150,000	3,040,500		Mar 04 06:54 PM

Open in Screener

TENX

Tenax Therapeutics Inc

Feb 13 • 04:00PM ET

12.65

-0.27 -2.09 %

Healthcare • Biotechnology • USA • NASD

TENX Tenax Therapeutics Inc daily Stock Chart

Peers: MRSN ACHV PBYI SCYX AVIR LXRX HURA EPIX PLX MRKR

| Held by: VTI VXF DFAS DCOR

Index	-	P/E	-	EPS (ttm)	-1.13	Insider Own	23.35%	Shs Outstand	5.91M	Perf Week	-0.63%
Market Cap	78.98M	Forward P/E	-	EPS next Y	-2.75	Insider Trans	1.57%	Shs Float	4.79M	Perf Month	-30.76%
Enterprise Value	-20.39M	PEG	-	EPS next Q	-0.41	Inst Own	90.54%	Short Float	2.50%	Perf Quarter	80.97%
Income	-43.33M	P/S	-	EPS this Y	-19.37%	Inst Trans	78.20%	Short Ratio	0.51	Perf Half Y	112.61%
Sales	0.00M	P/B	0.78	EPS next Y	-100.57%	ROA	-42.77%	Short Interest	0.12M	Perf YTD	3.77%
Book/sh	16.29	P/C	0.79	EPS next 5Y	-27.39%	ROE	-44.80%	52W High	18.38 -31.18%	Perf Year	73.29%
Cash/sh	15.91	P/FCF	-	EPS past 3/5Y	92.30% 77.86%	ROIC	-45.03%	52W Low	4.63 173.22%	Perf 3Y	-85.49%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	6.47% 8.25%	Perf 5Y	-99.71%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	92.89%	Oper. Margin	-	ATR (14)	1.07	Perf 10Y	-99.98%
Dividend Ex-Date	-	Quick Ratio	15.58	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	45.60	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	15.58	EPS Q/Q	-112.45%	SMA20	-7.95%	Beta	1.38	Target Price	25.25
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	-0.95%	Rel Volume	0.61	Prev Close	12.92
Employees	6	LT Debt/Eq	0.00	Earnings	Nov 12 AMC	SMA200	57.38%	Avg Volume	233.12K	Price	12.65
IPO	Apr 04, 1994	Option/Short	No / Yes	EPS/Sales Surpr.	-28.00% -	Trades		Volume	143,049	Change	-2.09%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-08-25	Initiated	Piper Sandler	Overweight	$20
Oct-24-24	Initiated	Leerink Partners	Outperform	$16
Oct-14-24	Initiated	Guggenheim	Buy	$16
Sep-30-24	Initiated	William Blair	Outperform
May-18-17	Upgrade	Ladenburg Thalmann	Neutral → Buy
Dec-16-14	Initiated	MLV & Co	Buy	$7
Nov-18-14	Initiated	WallachBeth	Buy	$12

Feb-04-26 07:00AM	Tenax Therapeutics to Participate in the Guggenheim Emerging Outlook Biotech Summit 2026 (GlobeNewswire)
Jan-08-26 02:00PM	Guggenheim Doubles Tenax (TENX) PT, Names Stock Top Pick (Insider Monkey)
Dec-17-25 09:16AM	Tenax Therapeutics Announces Result of Prespecifed Blinded Sample Size Assessment (GlobeNewswire) +5.65%
Nov-25-25 07:00AM	Tenax Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-12-25 04:17PM	Tenax Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Loading…
04:05PM	Tenax Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-06-25 07:00AM	Tenax Therapeutics to Host Virtual KOL Call to Discuss TNX-103 (Oral Levosimendan) for the Treatment of PH-HFpEF (GlobeNewswire)
Nov-03-25 07:00AM	Tenax Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference (GlobeNewswire)
Sep-16-25 07:00AM	Tenax Therapeutics Announces European Patent Office Intention to Grant Patent Covering Use of Levosimendan in PH-HFpEF (GlobeNewswire)
Aug-28-25 07:00AM	Tenax Therapeutics to Participate in the Cantor Global Healthcare Conference 2025 (GlobeNewswire)
Aug-13-25 04:17PM	Tenax Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Tenax Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
May-14-25 04:38PM	Tenax Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Tenax Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-16-25 04:29PM	Tenax: Phase 3 Heart Failure Program Continues With 2 Key Catalysts (Seeking Alpha)
08:00AM	Loading…
Mar-31-25 08:00AM	Tenax Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-25-25 04:25PM	Tenax Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Tenax Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-05-25 08:47AM	Tenax Therapeutics Announces $25 Million Private Placement (GlobeNewswire)
08:42AM	Tenax Therapeutics Expands Phase 3 LEVEL Program, Advancing Two TNX-103 (Oral Levosimendan) Registrational Studies for the Treatment of PH-HFpEF (GlobeNewswire)
Mar-03-25 08:00AM	Tenax Therapeutics to Participate in the Leerink Partners 2025 Global Healthcare Conference (GlobeNewswire)
Jan-31-25 09:00AM	Tenax Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference (GlobeNewswire)
Jan-22-25 08:00AM	Tenax Therapeutics Appoints Gillian Andor Vice President, Clinical Operations (GlobeNewswire)
Nov-13-24 07:19AM	Tenax Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Tenax Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update (GlobeNewswire)
Nov-04-24 07:30AM	Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of Directors (PR Newswire)
Oct-31-24 04:05PM	Tenax Therapeutics to Present at the Guggenheim Healthcare Innovation Conference (GlobeNewswire)
Aug-13-24 04:37PM	Tenax Therapeutics: Q2 Earnings Snapshot (Associated Press Finance) +11.63%
04:05PM	Tenax Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update (GlobeNewswire)
Aug-12-24 08:00AM	Tenax Therapeutics Announces Closing of $100 Million Private Placement and Plans to Accelerate the Oral Levosimendan Phase 3 Program (GlobeNewswire) -10.86%
07:13AM	Loading…
Aug-06-24 07:13AM	Tenax Therapeutics Announces Oversubscribed $100 Million Private Placement (GlobeNewswire) +28.77%
May-14-24 01:53PM	TENX Stock Earnings: Tenax Therapeutics Misses EPS for Q1 2024 (InvestorPlace)
08:10AM	Tenax Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
08:00AM	Tenax Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update (GlobeNewswire)
Apr-30-24 07:30AM	Tenax Therapeutics Announces New U.S. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF) (GlobeNewswire) +6.27%
Apr-09-24 08:30AM	Tenax Therapeutics to Host KOL Event: LEVEL Setting: the Scientific Rationale for Levosimendan as a Potential First Treatment for PH-HFpEF, and the Ongoing Phase 3 LEVEL Study (GlobeNewswire)
Mar-28-24 09:54PM	TENX Stock Earnings: Tenax Therapeutics Misses EPS for Q4 2023 (InvestorPlace) +9.56% -9.91%
08:30AM	Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial Results (GlobeNewswire)
Mar-12-24 08:30AM	Tenax Therapeutics to Present at the 36th Annual Roth Conference (GlobeNewswire)
Feb-29-24 09:00AM	Tenax Therapeutics Announces Oral Presentation of Levosimendan for the Treatment of PH-HFpEF at THT 2024 (GlobeNewswire) +10.87%
Feb-20-24 08:30AM	Tenax Therapeutics Announces Global License Amendment that Significantly Expands Rights to Levosimendan (GlobeNewswire)
Feb-08-24 08:53AM	Why Is Tenax Therapeutics (TENX) Stock Down 64% Today? (InvestorPlace) -64.45%
08:16AM	Tenax Therapeutics Announces Pricing of Approximately $9 Million Public Offering (GlobeNewswire)
Feb-07-24 08:01PM	Tenax Therapeutics Enrolls First Patient in Phase 3 LEVEL Study Evaluating TNX-103 (Oral Levosimendan) for the Treatment of Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF) (GlobeNewswire) +24.54%
Feb-06-24 08:30AM	Tenax Therapeutics Announces USPTO Grants Notice of Allowance for U.S. Patent Application, Significantly Broadening IP Protection for Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF) (GlobeNewswire) +31.31%
Dec-29-23 08:30AM	Tenax Therapeutics Announces Reverse Stock Split (GlobeNewswire) -16.79%
Nov-17-23 08:30AM	Tenax Therapeutics Announces Professor Javed Butler, M.D., M.P.H, M.B.A., joins PH-HFpEF Scientific Advisory Board (GlobeNewswire) -9.21%
Nov-14-23 05:05AM	Tenax Therapeutics: Q3 Earnings Snapshot (Associated Press Finance) -18.55%
Nov-13-23 03:22PM	Why Is Tenax Therapeutics (TENX) Stock Up 300% Today? (InvestorPlace) +297.44%
08:30AM	Tenax Therapeutics Announces FDA Clearance of IND for TNX-103 (oral levosimendan) for the Treatment of Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF), Initiation of Phase 3 sites expected 2023 (GlobeNewswire)
Aug-28-23 08:20AM	TENX: Second Quarter Results (Zacks) -5.96%
Aug-25-23 07:20AM	7 F-Rated Biotech Stocks You Shouldnt Touch With a 10-Foot Pole (InvestorPlace)
Jul-19-23 08:30AM	Tenax Therapeutics Issued U.S. Patent for Oral Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF) (GlobeNewswire) +10.40%
Jun-23-23 06:24AM	TENX: Notice of Allowance Increases Confidence (Zacks Small Cap Research) +9.19%
May-31-23 08:54AM	Tenax Therapeutics Achieves Major Milestone as USPTO Grants Notice of Allowance for U.S. Patent Application Covering Use of Oral Levosimendan (TNX-103) in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF) (GlobeNewswire) +13.31%
May-22-23 06:44AM	TENX: Prioritizing Levosimendan (Zacks Small Cap Research) +5.71%
Apr-21-23 03:59PM	10 Stocks Targeted By Short Sellers Recently (Insider Monkey)
Apr-12-23 02:50PM	Tenax Therapeutics Prioritizes Development Of TNX-103 For Heart Failure (Benzinga)
08:45AM	Tenax Therapeutics Provides 2023 Business Update (GlobeNewswire)
Apr-05-23 05:49AM	TENX: Patents Guide the Way (Zacks Small Cap Research) -7.89%
Mar-22-23 08:45AM	Tenax Announces Issuance of U.S. Patent Covering Use of IV Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF) (GlobeNewswire) -5.36%
Feb-17-23 07:05AM	Analysts Are Optimistic We'll See A Profit From Tenax Therapeutics, Inc. (NASDAQ:TENX) (Simply Wall St.)
Feb-15-23 08:05AM	TENX: New Funding Puts Wind in the Sails (Zacks Small Cap Research)
Feb-07-23 12:10PM	Triangle pharma raising millions amid uncertain future (American City Business Journals) -8.02%
Feb-03-23 08:19AM	Tenax Therapeutics Announces Pricing of Approximately $15.6 Million Public Offering (GlobeNewswire) -20.81%
Feb-02-23 10:43AM	Why Tenax Therapeutics Shares Are Gaining Today? (Benzinga) +30.77%
Feb-01-23 04:31PM	Tenax Granted Notice of Allowance for U.S. Patent Application Covering Use of IV Levosimendan in Pulmonary Hypertension with Heart Failure and Preserved Ejection Fraction (PH-HFpEF) (GlobeNewswire) -20.28%
Jan-04-23 08:00AM	Tenax Therapeutics Announces Reverse Stock Split (GlobeNewswire)
Nov-03-22 07:16AM	TENX: Agility Required to Unlock Considerable Upside (Zacks Small Cap Research) -20.03%
Oct-10-22 08:30AM	Positive Data Presented at HFSA Annual Meeting Demonstrate Effects of Oral Levosimendan in Patients with Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction (PH-HFpEF) (GlobeNewswire)
Sep-15-22 09:29AM	Tenax Therapeutics Stock Jumps On Strategic Alternative Review (Benzinga) +11.25%
08:30AM	Tenax Therapeutics Announces the Evaluation of Strategic Alternatives (GlobeNewswire)
Aug-28-22 09:23AM	Loss-Making Tenax Therapeutics, Inc. (NASDAQ:TENX) Expected To Breakeven In The Medium-Term (Simply Wall St.)
Aug-23-22 05:58AM	TENX: The Pressures On: Awaiting Phase 3 Start (Zacks Small Cap Research)
Jul-01-22 07:52AM	Chapel Hill company given extension to regain Nasdaq compliance (American City Business Journals) +6.07%
May-25-22 08:30AM	Tenax Therapeutics Hosting Key Opinion Leader Webinar on TNX-201: A Potential Treatment for Pulmonary Arterial Hypertension (PAH) (Business Wire)
May-23-22 08:30AM	Tenax Therapeutics Announces Successful Comparative Pharmacokinetic Study of TNX-201 for the Treatment of Pulmonary Arterial Hypertension (Business Wire) +6.92%
May-19-22 08:18AM	TENX: 1Q:22 Financial and Operational Review (Zacks Small Cap Research)
May-18-22 08:30AM	Tenax Therapeutics Announces $8 Million PIPE Offering Priced At-the-Market under Nasdaq Rules (Business Wire) +7.27%
Apr-01-22 09:25AM	TENX: 2021 Financial and Operational Review (Zacks Small Cap Research)
Mar-31-22 08:30AM	Tenax Therapeutics Reports Fiscal Year 2021 Results and Provides Business Update (Business Wire)
Mar-30-22 05:00PM	Tenax Therapeutics Announces Two Presentations at Upcoming American College of Cardiology Scientific Sessions (Business Wire)
Jan-31-22 04:10PM	Tenax Therapeutics Appoints Robyn Hunter to the Board of Directors (GlobeNewswire)
Jan-12-22 08:30AM	Tenax Therapeutics Granted U.S. Patent for the Subcutaneous Use of Levosimendan (TNX-102) (GlobeNewswire)
Jan-05-22 11:48AM	TENX: TNX-103 & TNX-201 Near Ready for Phase III (Zacks Small Cap Research)
Jan-04-22 08:30AM	Tenax Therapeutics Provides Update on TNX-102, TNX-103 and TNX-201 Clinical Programs (GlobeNewswire) -9.01%
Nov-18-21 11:54AM	TENX: Imatinib IND Cleared & PK Study Near End (Zacks Small Cap Research) -5.22%
Nov-16-21 08:30AM	Tenax Therapeutics Reports Third Quarter 2021 Results and Provides Business Update (Business Wire)
Oct-06-21 08:30AM	Tenax Therapeutics Announces Clearance of the Investigational New Drug Application for Imatinib in Pulmonary Arterial Hypertension (PAH) (Business Wire)
Sep-28-21 08:30AM	Tenax Therapeutics to Present at the Benzinga Healthcare Small Cap Conference (Business Wire) +7.69%
Sep-20-21 10:43AM	TENX: Second Quarter Results (Zacks Small Cap Research) -6.57%
Sep-09-21 08:00AM	Tenax Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference (Business Wire)
Aug-17-21 08:00AM	Tenax Therapeutics Reports Second Quarter 2021 Results and Provides Business Update (Business Wire)
Aug-12-21 08:00AM	Tenax Announces New Publication Highlighting Novel Levosimendan Mechanism of Action in Pulmonary Hypertension Patients with Heart Failure and Preserved Ejection Fraction (PH-HFpEF) (Business Wire) -5.49%
Aug-05-21 08:00AM	Tenax Therapeutics Announced KOL Webinar on Levosimendan for Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF) (Business Wire) +5.73%
Jul-16-21 12:40PM	SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Tenax Therapeutics, Inc - TENX (Newsfile)
Jul-07-21 08:00AM	Tenax Therapeutics Announces CEO Transition and $10 Million PIPE Offering Priced At-the-Market under Nasdaq Rules (Business Wire)
Jun-14-21 04:25PM	Hedge Funds Are Selling Tenax Therapeutics Inc (TENX) (Insider Monkey)
Jun-10-21 08:30AM	Tenax Therapeutics Set to Join Russell Microcap® Index (Business Wire)
Jun-07-21 04:52PM	SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Tenax Therapeutics, Inc - TENX (Newsfile)

Tenax Therapeutics, Inc. is a pharmaceutical company engaged in the development and commercialization of products for cardiovascular and pulmonary diseases. The company was founded on May 26, 1967 and is headquartered in Chapel Hill, NC.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Rich Stuart	Chief Medical Officer	Dec 09 '25	Buy	10.22	2,500	25,542	5,266	Dec 10 06:48 PM
Rich Stuart	Chief Medical Officer	Dec 08 '25	Buy	10.10	2,500	25,250	5,000	Dec 10 06:48 PM
Rich Stuart	Chief Medical Officer	Dec 04 '25	Buy	9.20	2,500	22,998	2,500	Dec 05 05:46 PM
Rich Stuart	Chief Medical Officer	Dec 03 '25	Buy	9.08	1,500	13,618	2,766	Dec 05 05:46 PM
Rich Stuart	Chief Medical Officer	Dec 02 '25	Buy	9.01	1,000	9,006	1,266	Dec 05 05:46 PM
Giordano Christopher Thomas	CEO	Nov 18 '25	Buy	7.75	1,612	12,500	1,612	Nov 20 06:38 PM
Giordano Christopher Thomas	CEO	Nov 20 '25	Buy	7.59	538	4,083	2,605	Nov 20 06:38 PM
Giordano Christopher Thomas	CEO	Nov 19 '25	Buy	7.51	455	3,417	2,067	Nov 20 06:38 PM
MCGAULEY THOMAS	Interim CFO	Nov 17 '25	Buy	7.25	6,000	43,490	5,000	Nov 19 07:01 PM
MCGAULEY THOMAS	Interim CFO	Nov 17 '25	Buy	7.34	2,000	14,674	2,000	Nov 19 07:01 PM
Almenoff June Sherie	Director	Nov 18 '25	Buy	7.52	1,900	14,280	1,993	Nov 19 06:43 PM
Almenoff June Sherie	Director	Nov 17 '25	Buy	7.15	93	665	93	Nov 19 06:43 PM

NAMS

NewAmsterdam Pharma Company NV

TENX

Tenax Therapeutics Inc

Upgrade your FINVIZ experience